|
Orthologous residues
|
|
FLNA (human): S2152‑p, FLNA iso2 (human): S2144‑p, FLNA (mouse): S2152‑p, FLNA (rat): S2144‑p
|
|
Characterization
|
|
Methods used to characterize site in vivo:
[32P] bio-synthetic labeling, mutation of modification site
|
|
Disease tissue studied:
breast cancer, melanoma skin cancer
|
|
Relevant cell lines - cell types - tissues:
A7 (melanocyte), M2 (melanocyte), MCF-7 (breast cell)
|
|
Cellular systems studied:
cell lines
|
|
Species studied:
human
|
|
Enzymes shown to modify site in vitro:
|
|
|
|
Upstream Regulation
|
|
Potential in vivo enzymes for site:
|
|
Type
|
Enzyme
|
Evidence
|
Notes
|
|
KINASE
|
PAK1 (human)
|
pharmacological activator of upstream enzyme, transfection of dominant-negative enzyme, microscopy-colocalization, transfection of constitutively active enzyme, inhibition of upstream enzyme, co-immunoprecipitation
|
|
|
|
Treatments, proteins and their effect on site modification:
|
|
Treatments
|
Referenced Treatments
|
Manipulated Protein
|
Referenced Protein
|
Effect
|
Notes
|
|
heregulin
|
|
|
|
increase
|
|
|
peptide inhibitor
|
heregulin
|
|
|
inhibit treatment-induced increase
|
PAK1 auto-inhibitory domain
|
|
|
Downstream Regulation
|
|
Effect of modification (process):
cytoskeletal reorganization
|
